TWST: Do you feel that your company is fairly well understood in the financial markets? Mr. Passeri: Our company has been in transition, and I think it has been viewed historically as an early stage pre-clinical company. We have, I believe, through the external partnerships and the progress we’ve made on our internal programs, positioned ourselves well to take it to the next level. I think that the story has been articulated well; it just needs to be reiterated and communicated consistently and, as you know, in this business, proof is in the pudding; so it’s really all about execution. I think we will receive more of a positive profile when these programs get into the clinic and when we have a portfolio of assets that are working their way through clinical trials. TWST: How active are you in getting your message out to shareholders and potential shareholders? Mr. Passeri: I think the first year and a half that I was the President and CEO, I spent most of my time refining the plan and executing on that plan, and simply did not have the bandwidth to spend a significant amount of time networking with fund managers. Now that we’ve executed on the initial stages of that overall development plan, we will invest far more time on that endeavor. I do believe that the awareness of Curis has been increasing. We received significant positive feedback on the logic of the business model and the attractiveness of our multiple partnerships and programs. TWST: What are the key messages you would wish to convey to investors? Mr. Passeri: I think the primary message to differentiate Curis from a lot of the other biotechnology companies is the fact that we have a broad portfolio of assets based on multiple different technologies rather than a one-trick pony with one program being pushed through to the clinic. We believe that we have taken a pragmatic approach to creating a stable foundation through our corporate partnerships. I think the partnerships themselves speak volumes for the quality of the underlying science and validate the approach that we’re using to develop drug candidates. That approach, we believe, provides shareholders with more risk mitigation and risk management, while on the flip side, provides substantial upside not just through the partnership revenue but also in our retained programs. TWST: Thank you. DANIEL R. PASSERI President & CEO Curis, Inc.
First, I am not one of the bashing shorts. I had my Curis for some time. I sold it all about a week ago thinking the value would decay and I could buy back in at a lower price. I am not sure what to believe anymore. I don't see a short-term appreciation. I keep asking myself; How could a management team be smart enough to lead such a complex development process and dumb enough to dump their shares if they believed a major jump in price was on the way. I think Curis has much potential but I think its at least 18 - 24 months out.
I have to agree on support of the stock publicly as far as insider buy/sell.
I KNOW that they get options, but even if certain members of the Management team could buy 5K or 10K shares in the open market it would provide a public display of support at these levels. Instead we get McNabb's big sub-$5 option sell sticking out there staring us in the face.
Except for one shareholder the "shares" were expiring options. The chairman who sold some has well over a million. If I were him, I would also have sold a few, but he still has a huge, financially vested interest in success of company